LA SETA CATAMANCIO, SIMONA
 Distribuzione geografica
Continente #
EU - Europa 752
NA - Nord America 509
AS - Asia 196
SA - Sud America 6
AF - Africa 2
OC - Oceania 1
Totale 1.466
Nazione #
US - Stati Uniti d'America 486
GB - Regno Unito 344
SE - Svezia 122
CN - Cina 91
DE - Germania 67
IT - Italia 63
UA - Ucraina 43
TR - Turchia 40
KR - Corea 28
IE - Irlanda 24
CA - Canada 23
IN - India 21
RU - Federazione Russa 20
FR - Francia 17
EU - Europa 16
FI - Finlandia 16
NL - Olanda 14
SG - Singapore 8
CO - Colombia 6
GR - Grecia 6
HK - Hong Kong 6
BE - Belgio 5
RO - Romania 5
CH - Svizzera 2
EG - Egitto 2
ES - Italia 2
PL - Polonia 2
AU - Australia 1
IL - Israele 1
IR - Iran 1
Totale 1.482
Città #
Southend 322
Chandler 94
Wilmington 30
Princeton 29
Woodbridge 29
Jacksonville 28
Beijing 26
Milan 26
Dublin 24
Redmond 23
Seattle 22
Nanjing 18
Toronto 17
Ann Arbor 16
Fairfield 15
Ashburn 14
Dearborn 14
Roxbury 14
Somerville 14
Sakarya 13
Bengaluru 11
Boardman 11
Des Moines 11
Mountain View 10
Auburn Hills 8
Serra 8
Mumbai 7
Andover 6
Athens 6
Bogotá 6
Fremont 6
Hong Kong 6
Houston 6
Jinan 6
Ottawa 6
Shenyang 6
Brussels 5
Grafing 5
Los Angeles 5
Pisa 5
Cambridge 4
Chicago 4
Nürnberg 4
Palaiseau 4
Phoenix 4
Shanghai 4
Changsha 3
Helsinki 3
Al Mansurah 2
Baotou 2
Bitonto 2
Hangzhou 2
Hebei 2
Hefei 2
Ningbo 2
San Diego 2
Tianjin 2
Verona 2
Zhengzhou 2
Arese 1
Bergamo 1
Brentwood 1
Brisbane 1
Fuzhou 1
Guangzhou 1
Jiaxing 1
Lanzhou 1
Lecce 1
London 1
Margão 1
Nanchang 1
Noginsk 1
Preston 1
Pskov 1
Redwood City 1
Roseville 1
Seoul 1
Shaoxing 1
Siena 1
Taizhou 1
Tel Aviv 1
Trenton 1
Warsaw 1
Totale 1.004
Nome #
Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects 189
Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection : in vitro studies of mixed virus infections 153
Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation 151
Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine 144
Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors 136
In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs 113
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215 105
In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure 98
Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine 92
Response to antiretroviral therapy in a patient with an uncommon codon 69 insertion in the human immunodeficiency virus type 1 reverse transcriptase 88
Effective inhibition of HIV-1 isolated from patients with acute primary HIV-1 infection by aminooxypentane-RANTES 83
Rapid onset of M184V mutation and phenotypic resistance to stavudine in zidovudine pre-treated HIV-1-infected individuals receiving the therapeutic regimens zidovudine plus lamivudine or stavudine plus lamivudine 81
Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure 78
In vitro inhibition of HIV-1 by Met-SDF-1β alone or in combination with antiretroviral drugs 46
Totale 1.557
Categoria #
all - tutte 3.385
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.385


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201934 0 0 0 0 0 0 0 0 15 10 9 0
2019/2020169 19 10 15 7 11 13 16 9 18 32 13 6
2020/2021221 12 11 27 1 19 10 13 21 36 10 54 7
2021/2022149 17 14 3 3 1 2 8 13 22 22 4 40
2022/2023252 19 35 21 42 31 49 1 22 17 1 10 4
2023/202463 4 12 4 3 29 4 1 6 0 0 0 0
Totale 1.557